Physician profile
Frances M Burns
NPI 1083688766
$9,510.54
in general payments reported to CMS, 2019-2025
27 companies · $2,756 in 2025
The $2,756 reported for 2025 was more than what 96% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $812 · 2023: $2,014 · 2024: $3,010 · 2025: $2,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,645 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,644.54 |
| Education | $135.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,730.31 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,235.04 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,145.22 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,041.53 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $845.43 | 2022-2025 | Auvelity |
| Lundbeck LLC | $657.22 | 2021-2025 | Rexulti |
| Alkermes, INC. | $462.33 | 2022-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $428.94 | 2022-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $286.88 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $265.28 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $218.45 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $193.49 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $171.76 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $168.92 | 2024-2025 | Qelbree |
| Bausch Health US, LLC | $148.97 | 2022-2025 | Aplenzin, Wellbutrin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $136.54 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $59.05 | 2023-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $45.77 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $42.62 | 2023-2024 | Jornay Pm |
| Genentech USA, INC. | $40.32 | 2021-2022 | |
| Brainsway USA INC | $37.52 | 2024 | Brainsway Deep Tms System |
| Noven Therapeutics, LLC | $37.12 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $33.39 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $31.30 | 2024-2025 | Subvenite |
| Azurity Pharmaceuticals, INC. | $17.91 | 2024 | Horizant |
| Idorsia Pharmaceuticals US INC | $15.29 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.